Potential Risk of Prolonged Gamma-linolenic Acid Use
To the Editor: The report by Leventhal and colleagues (1) did not address the potential risk of arachidonate accretion associated with prolonged use of gamma-linolenic acid. Because elongase is more active than delta-5-desaturase, the dihomo-gamma-linolenic acid content of tissue lipids is increased during administration of borage oil, and some of this is metabolized further to arachidonate. We found that 2 g/d of gammalinolenic acid given to previously obese women increased the arachidonate content of their serum phospholipids (2) . Gammalinolenic acid given to obese Zucker rats increased adipose triglyceride arachidonate fivefold compared with controls and reduced their food intake (3) . Elevated dihomo-gamma-linolenic acid in muscle phospholipids is associated with insulin resistance (4) . During relatively short periods of borage oil administration, the initial effects result from the increase in dihomo-gamma-linolenic acid. With prolonged administration (for example, >1 year), slow accumulation of arachidonate will eventually enhance the tissue content of this inflammatory mediator, which could counteract the early therapeutic effects of borage oil. After gamma-linolenic acid treatment is discontinued, the production of extra dihomo-gamma-linolenic acid ceases, and the residual effects of enhanced tissue arachidonate could include exacerbation of the arthritis. Thus, it would be important to have data on serum or tissue fatty acids and to know whether symptoms rebounded in study patients after drug discontinuation and in its absence. Physicians and patients should be alerted that a tissue buildup of arachidonate might promote subsequent inflammation, thrombosis, and immunosuppression (5).
In response: Dr. Phinney's remarks are well taken. Administration of gamma-linolenic acid might be expected to increase arachidonate levels by increasing conversion of dihomo-gamma-linolenic acid to arachidonate. Also, prostaglandin E x reduces phospholipase A 2 activity; thus, mobilization of arachidonate from phospholipid might be reduced. It is also possible that gamma-linolenic acid administration results in the movement of arachidonate from phospholipids, which normally provide arachidonate for prostaglandin production. We have not observed increased concentrations of total or phospholipid arachidonate in plasma or in peripheral blood leukocytes after administration of gamma-linolenic acid but we have not analyzed fatty acids in cells from patients receiving gamma-linolenic acid for more than 24 weeks, nor have we examined tissue triglycerides.
We have noticed worsening of synovitis in several patients after withdrawal of gamma-linolenic acid. We have considered this finding to be due to absence of the anti-inflammatory effects of the fatty acid. Arachidonate accumulation may lead to increased synovitis in the manner suggested by Dr. Phinney. We are investigating gamma-linolenic acid and arachidonate movement and metabolism in cells from patients receiving long-term (24 to 48 weeks) gamma-linolenic acid.
We agree with Dr. Phinney's note of caution. Gamma-linolenic acid in the doses we use must be considered experimental and should be administered by physician-investigators in a controlled setting.
Robert B. Zurier, MD
University of Massachusetts Medical Center Worcester, MA 01655
Morphine for Dyspnea in Patients with Cancer
To the Editor: We agree with Bruera and colleagues (1) that morphine alleviates dyspnea in patients with advanced cancer but are concerned about some of their findings and the study design. They detected no respiratory depression by pulse oximetry; however, most patients in our prospective trial of continuous-infusion morphine for dyspnea (2) showed progressive increases in PC0 2 and decreases in blood pH during serial arterial blood gas determinations. Bruera and colleagues' patients scored a mean of 30 on a 100-point dyspnea scale, suggesting only moderate dyspnea, whereas most of our patients were severely dyspneic. Milder dyspnea probably implies less pulmonary compromise and more resistance to the respiratory suppressive effects of morphine. A direct-dose comparison between the studies is difficult because Bruera and colleagues chose an arbitrary morphine dose (50% greater than the dose required for pain), whereas we titrated the doses to control dyspnea.
In Bruera and colleagues' study, pain was assessed only at baseline. The placebo-recipients probably experienced increased pain during the observation period, and the increased anxiety and discomfort may have affected their dyspnea scale.
The use of the subcutaneous route of morphine, which necessitated repeated injections, may also have increased discomfort and anxiety. Patients who cannot receive oral nutrition or medications, including narcotics, usually require intravenous access for hydration. Continuous intravenous morphine, as used in our study, is as safe and effective as intermittent injections and may be more convenient for both patients and staff (3, 4 In response: We read with interest the letter by Krasnow and colleagues. Differences in results of pulse oximetry (1) and end-tidal C0 2 (2) after an increase of 50% in the analgesic dose of morphine may be due to differences in patient population or, more likely, to the mode of administration of morphine (intermittent injection compared with continuous infusion). Although some patients present with continuous dyspnea, most experience wide diurnal variations in the intensity of their dyspnea. The use of continuous opiates presents the same problems as that observed in the management of incident pain (3): excessive dose when the symptom intensity is low and insufficient dose when it is high.
Krasnow and colleagues expressed concern about the possibility of increasing pain in the placebo group. In previous studies, we found that patients with good pain control show no significant increase in pain for approximately 60 minutes after the scheduled opioid dose (2) or after a dose of placebo (4) . For this reason, our assessments took place at 30, 45, and 60 minutes only. Finally, they state that patients who cannot receive medications and hydration orally usually require intravenous access for hydration. However, the overwhelming majority of our patients received parenteral medications and hydration only subcutaneously (5) . Using this route, patients have much greater mobility (hydration can be completed as a 2-hour bolus or overnight), their limbs are free, subcutaneous needles remain in place approximately 1 week, the overall cost is lower, and home management becomes easier. Nonetheless, more studies are needed to define the best mode of administration of opioids for dyspnea in patients with cancer.
Thrombocytopenia and Illicit Drug Use
To the Editor: To Cherubin and Sapira's comprehensive list of medical complications related to illicit drug abuse (1), we add several important thrombocytopenic syndromes. Severe, acute immune thrombocytopenia (platelet counts <20 x 10 9 /L) can occur in some patients after repeated injections of heroin (2) or cocaine (3). Quinine-dependent, platelet-reactive IgG, triggered by the use of quinine "filler" within the illicit drug preparation, has been implicated (4). In addition, chronic immune thrombocytopenia is an important complication of intravenous drug abuse (5), often as a manifestation of chronic human immunodeficiency virus (HIV) infection. Illicit drug use should be considered in patients with otherwise obscure acute or chronic thrombocytopenic syndromes.
Prednisone in Managing Rheumatoid Arthritis
To the Editor: The recent article by Laan and colleagues (1) was interesting and thought provoking. However, a practicing physician must consider how this information, which was gathered after less than a year of treatment, applies to long-term management of patients with rheumatoid arthritis. Physicians are certainly aware that osteoporosis can result from glucocorticosteroids, but their use is unavoidable and essential in the initial management of some patients, especially those with severe, aggressive rheumatoid arthritis. If these drugs are not used, the patient's activity level tends to decrease with attendant psychological problems and diminution in quality of life.
I certainly agree with the desirability of tapering oral corticosteroids when they are no longer needed for management, but I fear that the article may unduly dissuade clinicians from using appropriate doses of corticosteroids for fear of trabecular bone loss in their patients. I have reviewed many medical records involving physicians who have found corticosteroid use necessary for their patients with various inflammatory disorders. The patients in question took legal action against their treating physicians when osteoporosis and other corticosteroid side effects developed. In looking at the difficult problem of managing patients with rheumatoid arthritis on a day-to-day basis, one must look at the entire picture, which could entail 20 or 30 years of treatment.
A low degree of physical activity (that is, a sedentary lifestyle) is an independent risk factor for osteoporosis. In the long run, would it not be better for patients to be judiciously treated with oral corticosteroids and enrolled in exercise programs or other activities than not to be given treatment because of fears of osteoporosis? Although I do not believe that the authors intended to say that corticosteroids are contrain-dicated, I am convinced that these findings could be taken out of context. In response: Both the activity of the inflammatory process and the functional impairments that are the consequence of rheumatoid arthritis contribute independently to bone loss (1). We have presented evidence that low-dose glucocorticoids can cause rapid and marked trabecular bone loss despite an improvement in disease activity and functional capacity (2) . We also showed that this effect may be reversed after discontinuing therapy. After correcting for possibly confounding factors, others (3, 4) have found long-term use of prednisone to be associated with decreased bone mass in the spine and forearm.
We certainly agree that glucocorticoids are necessary for the management of some patients with rheumatoid arthritis. We suggest that the use of prednisone be limited to short periods as much as possible and that strategies to prevent bone loss be considered from the beginning and throughout glucocorticoid treatment. 
Death from an Unconventional Therapy for AIDS
To the Editor: Unconventional therapies are frequently used by human immunodeficiency virus (HlV)-infected patients (1). We describe a case in which an unconventional therapy contributed to a patient's death.
A 51-year-old man with the acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis, and disseminated Mycobacterium avium complex infection, having read about the purported value of hydrogen peroxide therapy in human immunodeficiency virus (HIV) infection, injected 35% hydrogen peroxide into his subclavian vein catheter. He subsequently developed nausea, dark urine, hypotension, and tachycardia, and was hospitalized. He had a hemoglobin concentration of 33 g/L (previously, 81 g/L), a creatinine level of 310 mmol/L (normal, <110 mmol/L), and a lactate dehydrogenase level of 41.92 ^tkat/L (normal, <3.33 jukat/L). His urine was dark brown and tested strongly positive for blood and free hemoglobin. The peripheral smear showed poikilocytosis, eccentrocytosis, and many Heinz bodies (Figure 1) . Treatment was initiated with intravenous fluids, urine alkalinization, and erythrocyte transfusions. Progressive renal insufficiency with multiple electrolyte abnormalities developed, and the patient died on the fifth hospital day.
Many HIV-infected patients use some form of unconven- tional therapy (39% in one survey [1] ), often without the knowledge of their physician. Acupuncture, massage, meditation, megavitamins, and many other therapies have been promoted as beneficial for HIV infection (2) . Hydrogen peroxide has also been touted for HIV infection and has been described as a "substance with 'magical' powers," found "at Lourdes, France" (3). However, serious adverse effects from hydrogen peroxide "therapy" have been reported (4). In our patient, Heinz body hemolytic anemia occurred when the oxidant stress of hydrogen peroxide infusion exceeded the protective capacity of the erythrocyte hexose monophosphate shunt system (5 
Primary Selective IgA Deficiency
To the Editor: A 54-year-old butcher was referred because of a suspected right renal hemorrhagic infarction. Computed tomography showed thrombosis of the common iliac veins, inferior vena cava, and right renal vein. Intravenous heparin, followed by oral warfarin, resulted in the recanalization of the inferior vena cava, common iliac veins, and deep venous circle of the limbs.
In the past 20 years, he had had many episodes of leg thrombophlebitis. He had no familial history of coagulation
He was thrombocytopenic (platelet count, 500 to 700 x 10 9 /L) as he had been for the past decade, with circulating and adherent IgG antiplatelet antibodies. The C4 complement fraction was reduced (6 to 10 mg/dL; normal, 15 to 45 mg/dL); the antinuclear antibody titer was 320, anti-Ro/SS-A antibodies were present, and a direct Coombs test was positive. There were no antinative DNA autoantibodies, cryoagglutinins, or circulating immunocomplexes. Lupus anticoagulant activity was detected. The IgG and IgM anticardiolipins were 21.3 GPL units with a cut-off of 15 and 25.6 MPL units with a cut-off of 13, respectively, but IgA anticardiolipins were absent. The VDRL was negative. Serum protein electrophoresis showed a broad and high (32% to 47%) gammaglobulin band, present for 10 years. High IgG polyclonal levels (2600 to 3300 mg/dL; normal, 800 to 1800 mg/dL) and low IgA concentrations (7.6 to 15 mg/dL; normal, 60 to 400 mg/dL) were noted; his IgM was normal. Exposure to drugs known to result in IgA deficiency was ruled out.
This patient did not fulfill the diagnostic criteria for systemic lupus erythematosus or other defined autoimmune syndromes. Although several autoimmune diseases are associated with IgA deficiency (1) and although anticardiolipin is the most frequent antibody in this immunodeficiency (2), the antiphospholipid syndrome has never been described. This is the first report of an association between the two conditions.
A proposed association between severe thromboembolic disease and IgA antiphospholipids has been suggested (3). However, Asherson and colleagues (4) observed that IgA antiphospholipids were not associated with thrombosis in the Sjogren syndrome. The condition of our patient is consistent with this observation (that is, non-IgA antiphospholipids associated with severe thrombosis) and supports the idea that IgA antiphospholipids have a low thrombogenicity (4).
Giovanni Gambaro, MD Amelia Ruffatti, MD, PhD Augusto Antonello, MD Istituto di Medicina Interna Policlinico Universitario 35120 Padova Italy

Myocardial Infarction in a Patient Who Smoked while Wearing a Nicotine Patch
To the Editor: Transdermal nicotine was introduced in 1992 to treat tobacco dependence. Although the use of nicotine patches in patients with coronary artery disease is appealing, its safety is unclear. We recently treated a patient who, while wearing a nicotine patch, had an acute myocardial infarction soon after starting to smoke a cigarette.
Our patient, a 47-year-old male smoker, suffered an inferior myocardial infarction in December 1991. Coronary arteriography at another institution showed a subtotal stenosis of the mid-right coronary artery and only a 50% stenosis of the left anterior descending artery. He stopped smoking and began wearing a 21-mg nicotine patch. One week later, while continuing to wear the patch, he smoked a cigarette for approximately 5 minutes and developed severe chest pain radiating to his left arm and jaw. Thirty minutes later, an electrocardiogram showed ST elevation in the anterolateral leads, and thrombolytic therapy was administered. He was transferred to our institution for cardiac catheterization, which showed that the infarction was caused by a new subtotal occlusion of the proximal left anterior descending artery.
Nicotine increases blood pressure and heart rate both directly and through activation of the sympathetic nervous system, thus increasing myocardial oxygen consumption (1). Nicotine can provoke angina in patients with coronary artery disease and can also trigger infarction. Muller and colleagues (2) hypothesized that activities associated with increased catecholamine levels can both trigger plaque rupture and promote the occlusive thrombus formation that can result in myocardial infarction or sudden cardiac death. Nicotine, by evoking the release of catecholamines (1), stimulating platelet aggregation (3), and increasing platelet-vessel wall interactions (3), may be a potent trigger of myocardial infarction.
During cigarette smoking, nicotine is rapidly absorbed, producing peak blood levels of about 15 ng/mL within the first few minutes (1), whereas a 21-mg transdermal nicotine patch produces peak blood levels of about 18 ng/mL between 5 to 6 hours after application (4). Thus, nicotine levels would be markedly elevated when the patch and smoking are combined, especially within the early minutes of smoking. We postulate that high plasma nicotine concentrations produced by the combination of smoking and nicotine patch use triggered the acute infarction in our patient.
Just as it is important for these patients not to smoke after presenting with an ischemic event, it is also unwise to start them on nicotine patches once discharged because of potential adverse cardiovascular effects of nicotine (5) . Furthermore, patients with coronary artery disease should be advised that the high nicotine levels produced when smoking is combined with nicotine patch use may trigger myocardial infarction. 
Simplified Bedside Thoracentesis
To the Editor: Although thoracentesis is generally considered to be well tolerated and safe, variations in the thoracentesis catheter, the need for ultrasound guidance, and the experience required of the person doing the procedure have all been questioned (1-4). In our search for a safer method of thoracentesis, we have begun doing diagnostic thoracentesis using a Vacutainer (Becton-Dickinson, Rutherford, New Jersey) blood-taking apparatus in a manner similar to that used in blood taking. The prepared skin is penetrated with the needle, and suction is applied while the needle is still in the soft tissue. The needle is then advanced into the pleural space. This technique is advantageous in that it uses equipment that is readily available and familiar to almost all physicians, and it costs less than one tenth of the price of commercially prepared thoracentesis kits. It also provides less exposure to body fluids because specimens are collected directly into the appropriate test tube.
We retrospectively reviewed 26 consecutive diagnostic thoracenteses done using this technique. The technique was suc-cessful in 25 of 26 cases and on the first attempt in 24. More than 65% of patients found the procedure to be less painful than venipuncture. No pneumothoraces were detected on postprocedure inspiratory and expiratory chest radiographs. This finding compares favorably with pneumothorax rates quoted in the literature (4% to 30% combined diagnostic and therapuetic [1] [2] [3] [4] ) and with 6 of 85 (7%) diagnostic thoracenteses retrospectively reviewed in our hospital (unpublished data). Admittedly, the size and design of our study preclude rigorous comparisons.
To our knowledge, this simplified technique has never been described in the medical literature. It should be included in future studies assessing the safety and diagnostic utility of thoracentesis.
Bert Govig, MD Marc Baltzan, MD
Sir Mortimer B. Davis Jewish General Hospital Montreal, Quebec J9T-252 Canada
Atrial Myxoma Mimicking Lyme Disease
To the Editor: We report an unusual case in which misinterpretation of clinical or serologic findings led to overdiagnosis and overtreatment of Lyme borreliosis.
In October 1992, a 46-year-old man developed multiple, slowly enlarging annular erythematous lesions on his legs. These were accompanied by fatigue, headache, low-grade fever, myalgias, and arthralgias. Because of a history of insect bites, an enzyme-linked immunosorbent assay (ELISA) for Lyme antibody was done. The test result was negative, and no laboratory test abnormalities were found. In December, he was admitted to a neurology department because of paresis of his right median nerve; cutaneous lesions and systemic symptoms persisted unchanged. Laboratory findings were normal again except for the presence of positive IgM antibody to Borrelia burgdorferi at low titer. The diagnosis of Lyme disease was suggested, and treatment with ceftriaxone (2 g/d for 15 days) was begun. Paresis and skin lesions resolved within a few days, but the patient's general condition did not significantly improve.
In February 1993, we saw him for the first time because his skin condition and constitutional symptoms had worsened. Physical examination showed annular erythematous-urticarial lesions and erythematous-purpuric papules on his thighs and legs. Histopathologic examination showed leukocytoclastic vasculitis of the dermal vessels with some extravasation of the erythrocytes. The patient had a faint IgG antibody response to the 31 KD antigen of B. burgdorferi, but indirect immunofluorescence and ELISA results were negative. Routine laboratory tests, chest radiographs, an electrocardiogram, and an echograph of the abdomen were normal. Finally, because of his disabling fatigue, echocardiography was done and showed the presence of a left atrial myxoma. A few days after surgical excision of the tumor, systemic symptoms and the skin lesions disappeared and have not recurred.
Atrial myxoma and Lyme disease should be regarded as "great simulators" because they can produce many clinical symptoms (2, 3) . Cardiac myxomas are frequently misdiagnosed as endocarditis, connective tissue disease, fever of unknown origin, or other neoplasms because they can appear with noncardiac manifestations or various skin lesions (4, 5) . This report also confirms that clinical findings and serologic tests suggestive of Lyme disease, coupled with an uncertain history of tick bites, must be regarded with caution before making a diagnosis.
Francesco Drago, MD Guido Nazzari, MD Franco Crovato, MD Chiavari Hospital Chiavari, Gensa Italy
Case Reports and Causality
To the Editor: The authors of the computer-generated casecontrol study of acute liver disease associated with certain antibiotics (1) correctly stated that "case reports and case series suffer from the absence of a control group, making any causal relations difficult to determine." It is also true that case-control studies done retrospectively from prospectively structured computer-stored data often do not permit the more creative insights that result from deeper analysis of individual cases.
However, it was an intensive study of a single case in 1961 (2) and a review of similar case reports that led to the conclusion that esterification at a particular site of the erythromycin molecule was responsible for the induction of cholestatic hepatitis; that erythromycin estolate, the ester of erythromycin base, was capable of inducing hepatitis on the basis of hypersensitivity rather than toxicity; and that the nonesterified erythromycin base lacked the capability of inducing hepatitis. Although this causal relation was difficult to determine by a full-time general internist, particularly more than 30 years ago, it did result in descriptive drug inserts by pharmaceutical companies that advocated caution regarding the possibility of erythromycin estolate-induced hepatitis. This relation is probably why the authors found no use of erythromycin estolate in their series. 
Fred
Surgeons and Internists
To the Editor: As another medical oncologist with a special interest in breast cancer, I can empathize with Dr. Susan Rosenthal's "Parable of the Surgeon and the Internist" (1). Patients diagnosed with breast cancer must be educated about and participate in decisions regarding treatment options during a most trying period in their lives. Surgeons, medical oncologists, and radiation oncologists must all possess outstanding communication skills and should consider themselves partners in this effort if progress against breast cancer is to be made.
Unfortunately, the literature on adjuvant treatment of breast cancer is voluminous. Legitimate differences regarding the management of individual cases have been the subject of panel discussions at national meetings. The implication that our surgical colleagues are less sophisticated in their approach to patients with breast cancer is untenable. Much of the research that forms the basis for our current standards of practice comes from the work of the National Surgical Adjuvant Breast and Bowel Project. This organization was started by a group of surgeons to compare mastectomy with more circumscribed surgery and continues to enroll more patients than any other cooperative group in trials to examine the effect of perioperative therapy on relapse rates.
Through active participation in tumor boards, grand rounds, and multispecialty clinics, we can ensure that all opinions are seriously considered and that patients benefit from our combined experience. Rather than publish derogatory statements focused at our surgical colleagues in prestigious internal medicine journals, we would do better to explore additional ways to improve communication and work together.
Christine S. Hunter, MD Commander, U.S. Navy Medical Corps Naval Medical Center San Diego, CA 92134
To the Editor: We read with interest the editorial (1) on dualphysician marriages because, as you note, "soon nearly half of all young physicians will be married to each other." As a married physician couple with two children whose academic jobs carry heavy clinical responsibility, we have found it difficult to study the uniqueness of this relationship here.
However, during a sabbatical in England, we studied the phenomenon of married doctor couples there (2, 3) . Although many of our findings also apply to married doctor couples in the United States, the system of postgraduate training in the United Kingdom usually requires several relocations and is clearly a detriment to women who generally defer to the husband's career. This tends to be by choice because these decisions are usually made during the prime child-bearing years.
Finally, our philosophy is that "whoever has the time does the work." We each have our favorite (or least repulsive) jobs, but to try to spread chores equally at all times is just another stressor. If both parties actively work toward continued success of the marriage, you don't have to count points.
Rewarding Women in Academic Medicine
To the Editor: In their comparison of the status of women and men in academic medicine, Carr and colleagues (1) might have arrived at more tangible conclusions if they had evaluated their data differently. They compared men with women whose year of graduation from medical school was, on average, 5 years later. Not surprisingly, the women had lower pay and academic rank. It would have been much more valid and informative to compare them with men of similar seniority, data that were available to the authors from their survey. Was this done? A similar correction factor should have been made for extent of training, which differed significantly.
Another factor not evaluated by the authors was the effect that maternity leave might have had in delaying the rewards of academic excellence among women, who may have had many months, if not years, subtracted from their professional lives to raise their infant children.
If men and women in academic medicine are all to be considered "apples" and not "apples and oranges" in terms of advancement, we must at least select apples of equivalent age and cultivation.
Allen B. Weisse, MD Springfield, NJ 07081
